Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3BNC117 and 10-1074 in HIV-infected Individuals
NCT03526848Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Jun 2018
- Primary completion
- Sep 2021
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Rockefeller University. Primary endpoints: Change in the size of the functional, latent HIV-1 reservoir at Week 26, Size of the proviral HIV-1 reservoir at 48 weeks and 4 more. Started Jun 2018; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03526848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526848.